Publiziert in: Marktpuls, Unternehmen
Frei
Alcon - Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2 Dienstag, 20. Oktober 2026 - 22:36
Alcon has added a new press release to its website:
Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2
Click here for a complete listing of Alcon press releases.
Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2
Click here for a complete listing of Alcon press releases.